pirfenidone has been researched along with Cardiac Remodeling, Ventricular in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aimo, A; Bayes-Genis, A; Burchielli, S; Emdin, M; Galvez-Monton, C; Iborra-Egea, O; Martini, N; Panichella, G; Passino, C | 1 |
| Aimo, A; Aquaro, GD; Barison, A; Burchielli, S; Emdin, M; Masotti, S; Modena, M; Musetti, V; Passino, C; Pucci, A; Terlizzi, D | 1 |
| Adamo, L; Bajpai, G; Barger, PM; Bhattacharya, D; Jiang, W; Kovacs, A; Mann, DL; Matkovich, SJ; Rocha-Resende, C; Schilling, JD; Staloch, LJ; Weinheimer, CJ | 1 |
| Chen, J; Li, H; Wang, Y; Wu, Y; Zhao, S | 1 |
| Czubryt, MP; Roche, P | 1 |
| Ding, C; Marcus, GM; Nguyen, DT; Olgin, JE; Wilson, E | 1 |
1 trial(s) available for pirfenidone and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study.
Topics: Animals; Cicatrix; Fibrosis; Humans; Male; Myocardial Infarction; Rats; Rats, Wistar; Ventricular Remodeling | 2023 |
5 other study(ies) available for pirfenidone and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis.
Topics: Animals; Computational Biology; Fibrosis; Myocardial Infarction; Myocardium; Pyridones; Swine; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury.
Topics: Animals; B-Lymphocyte Subsets; Diphtheria Toxin; Disease Models, Animal; Female; Heart Ventricles; Humans; Lipopolysaccharides; Lymphocyte Activation; Lymphocyte Depletion; Mice; Myocardial Infarction; Myocardium; Pyridones; Reperfusion Injury; Ventricular Remodeling | 2018 |
Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Collagen; Constriction; Fibrosis; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Interleukin-1beta; Male; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Myocytes, Cardiac; Myofibroblasts; NLR Family, Pyrin Domain-Containing 3 Protein; Pyridones; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Survival Rate; Transforming Growth Factor beta1; Ventricular Remodeling | 2013 |
Pirfenidone and the inflammasome: getting to the heart of cardiac remodeling.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Male; Myocardium; NLR Family, Pyrin Domain-Containing 3 Protein; Pyridones; Ventricular Remodeling | 2013 |
Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias.
Topics: Animals; Echocardiography; Electrophysiologic Techniques, Cardiac; Fibrosis; Heart Conduction System; Heart Ventricles; Male; Myocardial Infarction; Neural Conduction; Pyridones; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Ventricular Function, Left; Ventricular Remodeling; Voltage-Sensitive Dye Imaging | 2010 |